Shares of Incyte Corp. INCY slid 1.26% to $58.98 Friday, on what proved to be an all-around poor trading session for the ...

The laboratory services company has agreed to purchase certain assets of Incyte's clinical and anatomic pathology testing ...

Just before the May 5 trial date set for Novartis and Incyte to finally hash out their Jakafi royalty dispute in court, the ...

Sun Pharmaceutical Industries Ltd. can launch its new hair-loss drug Leqselvi after the Federal Circuit reversed a district ...

Incyte Corp raised the annual sales forecast for its blood cancer drug Jakafi on Tuesday, and said it expects minimal impact from U.S. tariffs due to its flexibility in sourcing supplies. CEO Hervé ...

Today, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Incyte Corp. v. Sun ...

Incyte (Nasdaq: INCY) announced its participation in the 2025 BofA Securities Health Care Conference. The company’s ...

Shares of Incyte Corp. INCY shed 4.03% to $59.61 Tuesday, on what proved to be an all-around rough trading session for the ...

Jakafi ® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to ...

Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 33,413 shares of the Company’s common stock and stock option awards to ...

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Incyte INCY in the ...

WILMINGTON, Del., May 07, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 33,413 shares of the Company ...